House of Commons
As this motion is using historical data, we may not have the record of the original ordering, in which case signatories are listed alphabetically.
TREATMENT OF ATRIAL FIBRILLATION
EDM #1208
Tabled 20 March 2014
2013-14 Session
That this House is deeply concerned that clinical commissioning groups and GPs across the country are failing to prescribe new oral anti-coagulants (NOACs), which are new life-saving drugs which prevent atrial fibrillation-related strokes; notes that these drugs have been approved by the National Institute for Health and Care Excellence; considers that the short-term cost of these drugs (Apixaban, Dabigatran and Rivaroxaban) is far outweighed by the cost of an atrial fibrillation-related stroke and other preventable illnesses; and recognises that the one million people with atrial fibrillation stand to benefit from NOACs wider use.

Signatures (40)

The first 6 Members who have signed to support the motion are the sponsors. The primary sponsor is generally the person who tabled the motion and has responsibility for it. The date shown is when the Member signed the motion.
In addition to the sponsors, the following Members have signed to support the motion.
These members had previously signed the motion, but have now withdrawn their support. The date shown is when the Member withdrew their signature from the motion.